The 13 most recent market catalysts affecting $NYXH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bearish
Impact 75
Unified Patent Court Issues Default Decision Against Inspire Medical Systems
Nyxoah SA has secured a default decision from the Unified Patent Court in Germany, ruling in its favor in a patent infringement case against Inspire Medical Systems. This decision …
Nov 6, 2026
Corporate Catalyst
Bearish
Impact 75
Nyxoah Reports Third Quarter 2026 Financial and Operating Results
Nyxoah reported a Q3 2026 operating loss of €21.9 million, an improvement from €24.4 million in Q3 2025, which is a positive sign for the company's financial health. This improveme…
Oct 19, 2026
Corporate Catalyst
Bearish
Impact 85
Nyxoah shares are trading lower after the company lowered its FY26 revenue guidance.
The lowered FY26 revenue guidance for Nyxoah (NYXH) is a direct and significant negative corporate catalyst. This indicates that the company anticipates slower growth or lower sale…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 75
Nyxoah Reports Preliminary Q3 Global Net Sales Of ~€9.2M, Up 19% QoQ; Lowers FY26 Global Net Sales From €36M-€40M To €33M-€35M
Nyxoah reported preliminary Q3 2026 global net sales of €9.2 million, showing strong sequential growth. However, the company simultaneously lowered its full-year 2026 revenue guida…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 75
Nyxoah Submits FDA Application To Expand Genio Indication To Complete Concentric Collapse Patients; Pivotal Data Show 74.3% Median Reduction In Apnea Events
This headline signals a significant corporate catalyst for Nyxoah (NYXH) as an expanded FDA indication for their Genio device would dramatically increase their addressable market w…
Sep 28, 2026
Corporate Catalyst
Neutral
Impact 65
Nyxoah Appoints Liam Kelly As CEO; Succeeds Oliver Taelman Oct. 1, 2026.
The appointment of Liam Kelly as CEO of Nyxoah, though effective in 2026, is a moderate corporate catalyst. Leadership changes can significantly influence a company's strategic dir…
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 65
Nyxoah Appoints Loic Moreau As Interim CFO, Effective Oct. 2, Succeeding John Landry; Reiterates FY26 Revenue Range Of €36M - €40M
Nyxoah announced a change in its Chief Financial Officer, with John Landry stepping down in October 2026 and Loïc Moreau taking over as interim CFO. While a CFO transition can some…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 85
Nyxoah shares are trading higher after the company announced that the ACCCESS U.S. pivotal study met its co-primary efficacy endpoint.
The successful completion of a pivotal study's co-primary efficacy endpoint is a major de-risking event for a medical device company like Nyxoah. This positive outcome significantl…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 85
Nyxoah's ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints
Nyxoah announced that its ACCCESS U.S. pivotal study for its sleep apnea treatment successfully met its primary safety and efficacy endpoints. This is a crucial development as it v…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 55
Cantor Fitzgerald Maintains Overweight on Nyxoah, Lowers Price Target to $6
Cantor Fitzgerald analyst Sarah James has revised her price target for Nyxoah (NYXH) from $11 to $6, a significant reduction, while keeping an 'Overweight' rating. This indicates t…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
Piper Sandler Reiterates Overweight on Nyxoah, Lowers Price Target to $6
Piper Sandler analyst Adam Maeder reiterated an 'Overweight' rating on Nyxoah (NYXH), signaling continued confidence in the company's long-term prospects. However, the simultaneous…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Nyxoah Lowers FY2026 Sales Guidance from $42.156M-$46.840M to $41.852M-$46.502M vs $44.410M Est
Nyxoah (NYXH) has revised its FY2026 sales guidance downwards, from a range of $42.156M-$46.840M to $41.852M-$46.502M. This new range is also below the analyst consensus estimate o…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 92
Nyxoah Q2 EPS $(0.67) Misses $(0.47) Estimate, Sales $8.922M Miss $9.030M Estimate
Nyxoah (NYXH) reported a significant miss on both its Q2 earnings per share and sales estimates. The company's loss of $(0.67) per share was 42.55% wider than the consensus estimat…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.